Interestingly, a recent study showed that SGLT2 inhibitor dapagliflozin promoted angiogenesis by upregulating VEGF expression, resulting in improved pathological findings and kidney function in the early‐stage diabetic nephropathy using a rat model of type 2 diabetes.31 This evidence concerns the gene VEGFA and diabetic kidney disease.